You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Spanish operations at oncopeptides.es
You are now leaving the global website of Oncopeptides AB, Sweden.
The link you clicked will take you the website of our Austrian operations at oncopeptides.at
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Italian operations at oncopeptides.it
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our German operations at oncopeptides.de
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Spanish operations at oncopeptides.es
You are now leaving the global website of Oncopeptides AB, Sweden.
The link you clicked will take you the website of our Austrian operations at oncopeptides.at
You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Italian operations at oncopeptides.it
Access to the information and documents on this part of the website is restricted for regulatory reasons. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.
DISCLAIMER – IMPORTANT
Due to applicable legal restrictions, the information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia), the United Kingdom, Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa or Switzerland, or any other jurisdiction in which such release, publication or distribution might constitute a violation of the local securities laws or regulations of such jurisdiction. We apologise for any inconvenience this may cause. Click here to return to the homepage.
Important information
Access to the information and documents on this portion of the website is restricted for regulatory reasons. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.
The information contained in this section of the website of Oncopeptides AB (publ) (the “Company”) (a) is only intended for, and may only be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to (i) persons resident and physically present outside the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the “United States”), Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa or Switzerland and resident and physically present in a jurisdiction where to do so will not constitute a violation of the local securities laws or regulations of such jurisdiction, and (b) does not constitute an offer to sell or the solicitation of an offer to buy or acquire, any securities of the Company in the United States, Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa, Switzerland or any other jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.
The securities of the Company referred to in this section of the Company’s website (the “Securities”) have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or with any securities regulatory authority of any state of the United States and may not be offered or sold within the United States unless the Securities are registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. In the United States, the Securities will be sold only to “qualified institutional buyers” (as defined in Rule 144A in the Securities Act) (“QIBs”), pursuant to an exemption from registration under the Securities Act. All offers and sales of the Securities outside the United States will be made in compliance with Regulation S under the Securities Act and in accordance with applicable law.
The Securities have not been and will not be registered under the applicable securities laws of Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa, Switzerland or any other jurisdiction in which it would be unlawful or would require registration or other measures, and therefore may not be offered or sold or for the account or benefit of any person having a registered address in, or located or resident in, Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa, Switzerland or any other jurisdiction in which it would be unlawful or would require registration or other measures.
In the United Kingdom, the information contained in this section of the Company’s website is only being distributed to and is only directed at “Qualified Investors” within the meaning of Article 2(e) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (the “EUWA”) (the “UK Prospectus Regulation”), who are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (ii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons above together being referred to as “relevant persons”). The Securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on the information contained in this section of the Company’s website.
This information and offering are only addressed to and directed at persons in member states of the European Economic Area (the “EEA”), who are “Qualified Investors” within the meaning of Article 2 (e) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with Qualified Investors. This information should not be acted upon or relied upon in any member state of the EEA by persons who are not Qualified Investors.
Access to the information contained in this section of the Company’s website may be illegal in certain jurisdictions, and only certain categories of persons may be authorised to access such information. All persons residing outside of Sweden who wish to have access to the information contained in this section of the Company’s website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this section of the Company’s website, or require registration or approval for any acquisition of Securities by them. No such registration or approval has been or will be obtained outside of Sweden.
The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
I therefore certify that:
1. I am (i) resident and physically present in a country outside the United Kingdom, the United States, Australia, Canada, Hong Kong, Israel, Japan, New Zealand, Singapore, South Africa and Switzerland or any other jurisdiction in which the release, distribution or publication would be unlawful or require registration or any other measure in accordance with applicable law or (ii) a Qualified Investor within the EEA, a relevant person in the United Kingdom;
2. I am authorised to access the information contained in this section of the Company’s website without being subject to any legal restriction and without any further action required by the Company; and
I have read, understand and agree to comply with all of the restrictions set forth above.
March 17, 2026 – Oncopeptides AB (publ) announces the outcome of the partially guaranteed rights issue of approximately SEK 200 million (the “Rights Issue”). The subscription period in the Rights Issue ended on 16 March 2026. The outcome shows that 77,082,970 ordinary shares, corresponding to approximately 60 percent of the offered ordinary shares, have been subscribed for by exercise of subscription rights in the Rights Issue. Additionally, applications for subscription of 3,096,716 ordinary shares without subscription rights, corresponding to approximately 2 percent of the offered ordinary shares, have been submitted. Therefore approximately 33 percent of the Rights Issue will be allocated to parties that have entered into guarantee commitments. The Rights Issue will provide the Company with approximately SEK 190 million before deduction of transaction costs related to the Rights Issue.
Find Q&A for investors, BioStock presentation, Redeye interview, Oncopeptalks, press releases and documents for the rights issue below.
Summary of the Rights Issue
Subscription period: 2–16 March 2026
Subscription price: SEK 1.55 per share
Terms: Existing shareholders (registered on the record date of 26 February 2026) will receive one subscription right for each existing common share. Each subscription right entitles the holder to preferential rights to subscribe for new common shares, where two (2) subscription rights entitle the holder to subscribe for one (1) new common share. In addition, investors will be able to apply for subscription of shares without subscription rights.
Guarantee: The rights issue is secured through subscription commitments from, among others, the largest shareholder HealthCap VIII LP, as well as guarantee undertakings from external investors, including DNB Bank ASA, for a total amount of approximately SEK 190 million.
Preliminary timetable for the Rights Issue
The below timetable for the Rights Issue is preliminary and may be adjusted.
Record date for the right to receive subscription rights
26 February 2026
Trading in subscription rights
2 – 11 March 2026
Subscription period
2 – 16 March 2026
Trading in paid subscribed shares (BTA)
2 – 23 March 2026
Announcement of the outcome of the Rights Issue
Around 18 March 2026
CEO Sofia Heigis presents Oncopeptides at Aktiespararna
March 11, 2026 – Oncopeptides CEO Sofia Heigis recently presented the company at an Aktiespararna event in Stockholm.
1. Why is Oncopeptides carrying out this rights issue right now, and what will the proceeds be used for?
Answer: We are carrying out this issue to strengthen our financial position and ensure we have the resilience required to reach a positive cash flow in 2027. The net proceeds will primarily be used to finance the ongoing commercialization of Pepaxti in Europe. In addition, a portion of the capital will be used for cost-effective development of our pipeline, specifically to initiate a human “window-of-opportunity” study to evaluate our candidate OPD5 in glioblastoma.
2. What are the conditions for participating in the rights issue, and what is the subscription price?
Answer: The subscription price is set at SEK 1.55 per new ordinary share. Anyone registered as a shareholder on the record date, February 26, 2026, will receive one (1) subscription right for each ordinary share held. Two (2) subscription rights are required to subscribe for one (1) new ordinary share. It is also possible to apply for the subscription of shares without the support of subscription rights.
3. How much will my holding be diluted if I choose not to participate in the issue?
Answer: If the rights issue is fully subscribed, the number of shares will increase by up to 129,283,736. For shareholders who choose not to participate at all, this means a dilution of their ownership stake by a maximum of approximately 33.3 percent. However, you have the opportunity to sell your subscription rights on the stock exchange (Nasdaq Stockholm) between March 2 and March 11, 2026, to fully or partially compensate yourself for the financial dilution effect.
4. Is the issue secured in advance through subscription commitments or guarantees?
Answer: Yes, to a very large extent. The company’s largest shareholder, HealthCap VIII LP, has committed to subscribing for shares worth SEK 20 million (corresponding to almost 10 percent of the issue). In addition, management and certain board members have committed to subscribing for approximately SEK 0.7 million. Furthermore, we have secured guarantee commitments (both bottom and top guarantees) from a number of investors totaling SEK 170 million. Together, the subscription and guarantee commitments cover approximately SEK 190 million of the total issue volume of up to SEK 200 million.
5. What are the most important dates I need to keep track of as a shareholder?
Answer:
February 26, 2026: Record date (you must be a registered shareholder to receive subscription rights).
March 2–11, 2026: Trading in subscription rights takes place on Nasdaq Stockholm. If you wish to sell your rights, this must be done no later than March 11; otherwise, they will expire worthless.
March 2–16, 2026: Subscription period. This is the window to subscribe and pay for new shares.
Around March 18, 2026: The outcome of the issue is announced.
6. If you successfully conclude a partnership agreement in Japan, how does that affect the need for this rights issue?
Answer: The rights issue is being carried out to secure our baseline plan: to reach a positive cash flow in 2027 organically and take our European business all the way to our goal. We are currently in negotiations regarding the licensing of Pepaxti in Japan, and if we successfully close this and receive licensing payments, we intend to use those additional funds to accelerate the development of our pipeline (primarily OPD5) toward indications such as glioblastoma and hematological diseases, where the potential market values are very large.
7. You mention that a portion of the capital will go to R&D for glioblastoma. How large are the risks and costs you are taking on in this venture?
Answer: Our approach is designed to be highly capital- and cost-efficient. The planned human “window-of-opportunity” study aims to quickly and efficiently generate evidence for further clinical development of our PDC platform in glioblastoma. To keep costs down, we have conducted a strategic review and will, going forward, base our research to a much greater extent on external and academic collaborations instead of maintaining heavy internal fixed costs.
8. Where do I turn for more information?
Answer: For questions regarding participation and the practicalities of the rights issue, please contact your bank. Oncopeptides cannot provide guidance on this, as we do not have insight into how specific banks handle the issue, which can vary. For questions regarding the motives for the issue and the company’s future ambitions, please contact ir@oncopeptides.com.
Biostock: presentation and interview with Sofia Heigis
Sofia Heigis, CEO of Oncopeptides, recently visited the Biostock studio to present the company, its’ ambitions for Pepaxti in Europe and rest of the world and also outline the company´s strategic pivot into a multi-indication global biotech, spearheaded by its glioblastoma project. The presentation is followed by a Q&A session with Jonas Söderström, managing partner at Biostock.
THIS INFORMATION MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL).
Press release
Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma
March 9, 2026
Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO) today announces that it has achieved key regulatory agreement with both the Swedish and Norwegian Medical Products Agencies (Läkemedelsverket, MPA and Direktoratet for medisinske produkter, DMP) regarding the design of its planned “Window-of-Opportunity” (WoO) study evaluating a Peptide Drug Conjugate (PDC) in glioblastoma. The study will be conducted in Norway, where DMP has granted fast-track designation.
Oncopeptides publishes disclosure document regarding rights issue
Februrary 26, 2026 – Regulatory press release
Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO) publishes disclosure document in connection with the Company’s new share issue with preferential rights for existing shareholders of approximately SEK 200 million, as resolved by the Board of Directors on 19 February 2026 by virtue of the authorization from the Annual General Meeting held on 22 May 2025 (the “Rights Issue”). The disclosure document has been registered with the Swedish Financial Supervisory Authority and is available at the Company’s website.
Please note that the application forms below are for shareholders who own shares directly. If you own shares through your bank, such as Avanza or Nordnet, you will be able to subscribe through them. Subscription rights for current shareholders will be distributed on March 2.
Oncopeptalks about the Q4 report 2025, rights issue and news about the pipeline
February 23, 2026 – In the latest episode of Oncopeptalks, David and Sofia talk about the newly released Q4 report, the ongoing rights issue and news about our pipeline. The video is available in Swedish with English subtitles. Select subtitles via the menu at the bottom of the video.
Oncopeptides CEO Sofia Heigis interviewed by Redeye about Q4 and the new share issue
February 19, 2026 – Redeye analyst Richard Remanius recently interviewed CEO Sofia Heigis about Q4 and the upcoming new share issue of approximately SEK 200 million. The interview is held in Swedish.
Oncopeptides carries out a rights issue of approximately SEK 200 million
February 19, 2026 – Regulatory press release
Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO) today announces that the Board of Directors has resolved to carry out a new share issue of approximately SEK 200 million with preferential rights for the Company’s existing shareholders based on the authorization granted by the Annual General Meeting on 22 May 2025. The Rights Issue is being carried out to strengthen the Company’s financial position, provide additional scope for the ongoing commercialization of Pepaxti in Europe, and advance the Company’s preclinical project for the indication glioblastoma to the clinical development phase, which includes conducting an initial so-called ’window-of-opportunity’ study in human.
